DALLAS CLARK: Open Payments
NPI 1578234357 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,224 in 106 payments from 33 companies in 2025. Trend: 2023 $3,176 · 2024 $3,414 · 2025 $2,224
Food & beverage: $2,224
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $239 |
| Amgen Inc. | 10 | $188 |
| ABBVIE INC. | 13 | $175 |
| Xeris Pharmaceuticals, Inc. | 9 | $161 |
| Abbott Laboratories | 3 | $160 |
| Dexcom, Inc. | 5 | $156 |
| BETA BIONICS, INC. | 6 | $135 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $107 |
| Almatica Pharma LLC | 4 | $100 |
| Alexion Pharmaceuticals, Inc. | 3 | $68 |
Products named: FREESTYLE LIBRE 3, Dexcom G6 Transmitter, Ozempic, iLet Bionic Pancreas, Kerendia, Wegovy, TERIPARATIDE, RECORLEV.
Industry payments across NV — which companies pay providers there.
